SELLAS Life Sciences Group, Inc. (SLS) Fair Value 2026

SLS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-08-28, SELLAS Life Sciences Group, Inc. (SLS) trades at $13.21. QOC: 5.1/10. Value Trap Risk: 25/100 (LOW). 0/13 models active.

Key Facts

Ticker
SLS
Price
$13.21
Quality Score
5.1/10
Value Trap Risk
25/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give SLS?

0 Intrinsic Value Models vs. Current Price ($13.21)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is SELLAS Life Sciences Group, Inc. (SLS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, SELLAS Life Sciences Group, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About SLS?

0 of 13 models are currently active for SLS. See which stocks rank higher →

How Does SLS Rank in Biotechnology?

Among 625 Biotechnology stocks, SLS ranks #298 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

SELLAS Life Sciences Group, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including gene therapy and cell therapy innovation — shape both the opportunity set and risk profile.

Is SLS a Value Trap?

CirclFi's Value Trap algorithm assigns SLS a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for SELLAS Life Sciences Group, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, SELLAS Life Sciences Group, Inc. scores 5.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SLS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy SELLAS Life Sciences Group, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

SERSerina Therapeutics, Inc.QOC 5.1CVKDCadrenal Therapeutics, Inc.QOC 5.1JUNSJupiter Neurosciences, Inc.QOC 5.1FULCFulcrum Therapeutics, Inc.QOC 5.1CYDYCytoDyn Inc.QOC 5.1EXOZeXoZymes, Inc.QOC 5.1HOWLWerewolf Therapeutics, Inc.QOC 4.5EPRXEupraxia Pharmaceuticals Inc.QOC 2.4INMBINmune Bio Inc.QOC 6.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: SER · CVKD · JUNS · FULC · CYDY · EXOZ · HOWL · EPRX · INMB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to SLS?

7 companies across all industries closest to SLS’s Quality of Company score of 5.1/10.

FACTFACT II Acquisition CorpQOC 5.1CRCECircle Energy, Inc.QOC 5.1NCTYThe9 LimitedQOC 5.1STKESol Strategies Inc.QOC 5.1MCAGMountain Crest Acquisition Corp. VQOC 5.1APLDApplied Digital CorporationQOC 5.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FACT · CRCE · NCTY · STKE · MCAG · APLD · NVDA

Where Does SLS Sit in CirclFi's Biotechnology Rankings?

SLS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About SELLAS Life Sciences Group, Inc.’s Valuation?

What is SELLAS Life Sciences Group, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for SELLAS Life Sciences Group, Inc. (SLS). The Quality of Company score is 5.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SLS overvalued or undervalued right now?

At $13.21, 0 of 0 active models suggest SLS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits SELLAS Life Sciences Group, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.1 mean for SLS?

SELLAS Life Sciences Group, Inc.'s QOC of 5.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SLS?

CirclFi analyzes SLS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is SLS a value trap in 2026?

SELLAS Life Sciences Group, Inc.'s Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns SELLAS Life Sciences Group, Inc. (SLS) a Quality of Company score of 5.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/SLS/ · Methodology
Primary sources for this SLS valuation
  • Financial statements: SELLAS Life Sciences Group, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001390478) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SLS as of ; valuations recomputed .